CT scans can play a role not just in diagnosing but also in monitoring non–cystic fibrosis bronchiectasis management, explained James D. Chalmers, MD.
James D. Chalmers, MBChB, PhD
Advertisement
James D. Chalmers, MBChB, PhD, is a professor of respiratory medicine at the University of Dundee in Scotland.
Articles by James D. Chalmers, MBChB, PhD
In the final clip, James D. Chalmers, MBChB, PhD, notes that while the FDA approval of brensocatib is a milestone, questions remain on optimal patient selection, long-term benefits, and further targeting inflammation.
Brensocatib, the first FDA-approved dipeptidyl peptidase 1 (DPP1) inhibitor for non–cystic fibrosis bronchiectasis, may have broader potential for other neutrophil-driven conditions, according to James D. Chalmers, MBChB, PhD.
James Chalmers, MBChB, PhD, highlights the reassuring safety and tolerability profile of brensocatib in patients with non–cystic fibrosis bronchiectasis.
James D. Chalmers, MBChB, PhD, explains that the ASPEN trial findings show that brensocatib reduces exacerbations, slows lung function decline at higher doses, and offers clinicians a long-awaited evidence-based treatment option.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Ongoing COVID-19 Circulation Linked to Increases in Health-Related Work Absences, Workforce Exits
2
After Narrow Miss in Phase 3 Study, IO Biotech Ponders Next Steps for Immune-Modulatory, Off-the-Shelf Cancer Vaccine
3
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
4
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
5
